Skip to main content
KANGSTEM BIOTECH CO., LTD. logo

KANGSTEM BIOTECH CO., LTD. — Investor Relations & Filings

Ticker · 217730 ISIN · KR7217730001 KO Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2025-07-09 Capital/Financing Update
Country KR South Korea
Listing KO 217730

About KANGSTEM BIOTECH CO., LTD.

https://kangstem.com

KANGSTEM BIOTECH CO., LTD. is a biopharmaceutical company that researches and develops advanced stem cell therapies. The company focuses on creating treatments for rare, incurable, and autoimmune diseases, with a pipeline that includes therapeutic candidates for neurological disorders. Leveraging proprietary technologies for the isolation and mass culture of mesenchymal stem cells, Kangstem Biotech also develops and commercializes stem cell culture media and related cosmetic products. The company is dedicated to addressing unmet medical needs through the development of next-generation biopharmaceuticals.

Recent filings

Filing Released Lang Actions
유상증자1차발행가액결정
Capital/Financing Update Classification · 100% confidence The document is an official announcement regarding the determination of the '1st issue price' (1차발행가액) for a paid-in capital increase (유상증자) by Kangstem Biotech. This relates directly to the company's capital structure and financing activities. According to the filing definitions, documents detailing fundraising or financing activities fall under the 'CAP' (Capital/Financing Update) category.
2025-07-09 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a capital increase (유상증자결정) for Kangstem Biotech. It details the correction of the issuance price (1차 발행가액 확정) and provides comprehensive details on the capital structure, share allocation, and subscription procedures. This falls under the category of announcements regarding new share issues or capital changes.
2025-07-09 Korean
권리락 (유상증자)
Share Issue/Capital Change Classification · 100% confidence The document is a short announcement regarding a 'rights offering' (유상증자) and the resulting 'ex-rights' (권리락) date for Kangstem Biotech. It provides specific details on the stock code, reference price, and the reason for the adjustment. Since it announces a capital change event (rights issue) rather than being a full report, it falls under the category of share issues or capital changes.
2025-07-09 Korean
[발행조건확정]증권신고서(지분증권)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Securities Registration Statement' (증권신고서) filed with the Financial Services Commission in South Korea. It specifically details a correction (정정) to a previous filing regarding the determination of the issuance price (발행조건확정) for a capital increase (유상증자). This document is a formal regulatory filing required for public offerings of securities, which falls under the 'Regulatory Filings' category as it is a specific legal disclosure document for capital market activities.
2025-07-09 Korean
투자설명서
Capital/Financing Update Classification · 95% confidence The document is a '투자설명서' (Investment Prospectus) issued by Kangstem Biotech on July 9, 2025. It details a capital increase (securities offering) of 38,000,000 shares, including subscription periods, offering prices, and detailed risk factors (business, financial, and regulatory risks). This document is a formal regulatory filing required for public offerings of securities. In the context of the provided categories, this fits best as a 'Proxy Solicitation & Information Statement' (PSI) or a general 'Regulatory Filing' (RNS). However, since it is specifically a prospectus for a capital raise, and 'PSI' is often used for shareholder meeting materials, 'RNS' serves as the most accurate fallback for this type of formal regulatory disclosure document.
2025-07-09 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under Article 147 of the Financial Investment Services and Capital Markets Act. This document notifies the market of a change in shareholding percentage or purpose by a major shareholder. In the provided taxonomy, this corresponds to a 'Major Shareholding Notification'.
2025-07-09 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.